A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
L
Larry Cripe, MD
Primary Investigator
Overview
The purpose of this study is to see if we lower the chance of AML returning or getting worse by adding a new drug to the usual combination of drugs.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acute Myeloid Leukemia
-
Age: Between 60 Years - 100 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Diagnosis of acute myeloid leukemia (AML) based on 2017 World Health Organization (WHO) criteria excluding acute promyelocytic leukemia with PML-RARA.
Note: Patients with myeloid sarcoma without bone marrow involvement, acute leukemia of ambiguous lineage or blast transformation of chronic myelogenous leukemia (CML) are not eligible. - No evidence of central nervous system involvement of AML.
For a full list of participation criteria, please visit clinicaltrials.gov.
Updated on
23 Apr 2024.
Study ID: 1904708908 (A041701)